Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
61.70
-1.25 (-1.99%)
At close: Mar 20, 2026, 4:00 PM EDT
61.70
0.00 (0.00%)
After-hours: Mar 20, 2026, 6:02 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 18 analysts that cover Cytokinetics stock have a consensus rating of "Strong Buy" and an average price target of $88.5, which forecasts a 43.44% increase in the stock price over the next year. The lowest target is $56 and the highest is $136.
Price Target: $88.5 (+43.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 9 | 8 | 8 | 8 | 9 | 9 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 16 | 16 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $84 → $100 | Buy | Maintains | $84 → $100 | +62.07% | Mar 18, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $74 → $75 | Buy | Maintains | $74 → $75 | +21.56% | Mar 17, 2026 |
| UBS | UBS | Hold Maintains $61 → $69 | Hold | Maintains | $61 → $69 | +11.83% | Mar 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $83 → $84 | Buy | Maintains | $83 → $84 | +36.14% | Feb 26, 2026 |
| Citizens | Citizens | Buy Maintains $88 → $96 | Buy | Maintains | $88 → $96 | +55.59% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
95.73M
from 88.04M
Increased by 8.73%
Revenue Next Year
392.42M
from 95.73M
Increased by 309.93%
EPS This Year
-6.69
from -6.54
EPS Next Year
-4.83
from -6.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 191.5M | 669.6M | |||
| Avg | 95.7M | 392.4M | |||
| Low | 58.8M | 308.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 117.5% | 599.5% | |||
| Avg | 8.7% | 309.9% | |||
| Low | -33.2% | 222.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.96 | -2.93 | |||
| Avg | -6.69 | -4.83 | |||
| Low | -7.09 | -5.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.